This study is currently not recruiting participants.

Phase II Placebo-controlled Trial of Lisinopril and Coreg CR? to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin?)

Investigating the Effects of an Investigational Medication on Heart Health in Breast Cancer Patients

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

This phase II trial is studying lisinopril and Coreg CR? to see how well they work compared with a placebo in reducing side effects in patients with HER2-positive breast cancer receiving trastuzumab.

Detailed description of study

The primary objective of this study is to determine if administration of lisinopril or Coreg CR?, compared to placebo, will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in patients receiving adjuvant, or neoadjuvant,therapy for HER2 positive breast cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication compared to a placebo in reducing heart-related side effects in patients with HER2-positive breast cancer. HER2-positive breast cancer is a type of breast cancer with higher levels of a protein that promotes the growth of cancer cells. The study aims to see if the investigational medication can lower the risk of heart problems caused by cancer treatment.

Participants will receive either the investigational medication or a placebo while undergoing cancer treatment. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will measure heart function to determine if the investigational medication helps in reducing heart-related side effects.

  • Who can participate: Participants must have HER2-positive breast cancer, be receiving adjuvant or neoadjuvant therapy, and be at risk of heart-related side effects from trastuzumab treatment. Age criteria should be specified if applicable.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo during their cancer treatment. Heart function will be monitored to assess any side effects.
Updated on 19 Feb 2024. Study ID: SCUSF0806

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team